- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
April 07, 2025 12:25 ET CHARLOTTE, N.C.--(GLOBAL NEWSWIRE)-- Adaptin Bio, Inc. (“Adaptin” or the “Company”), a biotechnology company focused on developing precision cancer therapies with improved delivery to the brain and other tissues, announced today the successful completion of a reverse merger of a wholly owned subsidiary of Unite Acquisition 1 Corp. with and into [...]
APTN-101 is a novel BRiTE therapeutic targeting the most aggressive form of brain cancer Unique mechanism of action of APTN-101 will be evaluated in Phase 1 first-in human clinical trial in glioblastoma CHARLOTTE, N.C.--(BUSINESS WIRE)-- Adaptin Bio, a biotechnology company focused on developing precision cancer therapies with improved delivery to the brain and other tissues, [...]